The validity of animal models of depression

Psychopharmacology

Volumn 83, Issue 1, 1984, Pages 1-16

  Willner, Paul ^a  

^a LONDON METROPOLITAN UNIVERSITY   (United Kingdom)

Author keywords

Animal models; Depression; Validity

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; AMPHETAMINE; ANTIDEPRESSANT AGENT; ATROPINE; BUTRIPTYLINE; CHLORDIAZEPOXIDE; CHLORPROMAZINE; CLOMIPRAMINE; CLORGYLINE; CYPROHEPTADINE; DESIPRAMINE; DIAZEPAM; DOPA; DOXEPIN; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; IPRINDOLE; IPRONIAZID; ISOCARBOXAZID; LYSERGIDE; MAPROTILINE; METHYLDOPA; METHYSERGIDE; MIANSERIN; MORPHINE; NIALAMIDE; NISOXETINE; NOMIFENSINE; NORTRIPTYLINE; OPIPRAMOL; OXAZEPAM; PHENELZINE; PROPRANOLOL; PROTRIPTYLINE; QUIPAZINE; RESERPINE; SALBUTAMOL; SCOPOLAMINE; TRANYLCYPROMINE; TRAZODONE; TRIMIPRAMINE; TRIPELENNAMINE; VILOXAZINE; YOHIMBINE; ZIMELDINE;

ANIMAL MODEL; CENTRAL NERVOUS SYSTEM; DEPRESSION; DRUG EFFICACY; DRUG THERAPY; METHODOLOGY; NONHUMAN; REVIEW; THERAPY;

5-HYDROXYTRYPTOPHAN; AMPHETAMINE; ANIMAL; BEHAVIOR, ANIMAL; CIRCADIAN RHYTHM; DEPRESSIVE DISORDER; DIHYDROXYPHENYLALANINE; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; HELPLESSNESS, LEARNED; HUMAN; KINDLING (NEUROLOGY); MOTOR ACTIVITY; OLFACTORY BULB; PREDATORY BEHAVIOR; RATS; RESERPINE; SELF STIMULATION; SOCIAL ISOLATION; STRESS, PSYCHOLOGICAL; YOHIMBINE;

EID: 0021348560     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/BF00427414     Document Type: Review

References (236)

1. Discussion of papers by Suomi and Bowlby
2. A biobehavioural approach to depression
3. External validating criteria for psychiatric diagnosis: Their application in affective disorders
4. Depressive disorders: Toward a unified hypothesis
5. The generality of learned helplessness in the rat
6. Variations in unsignalled inescapable preshock as determinants of responses to punishment
7. Effects of inescapable shock on subsequent escape performance: catecholaminergic and cholinergic mediation of response initiation and maintenance
8. Depression: The predisposing influence of stress
9. Testing a new theory of depression with an animal model: Neurochemical-behavioural evidence for postsynaptic serotonergic receptor involvement
10. A simple screening procedure for imipramine-like anti-depressant drugs
11. Antidepressives and the kindling effect
12. Neurophysiologic techniques and antidepressive activity
13. The pharmacology of seizures induced by sensitization with low intensity brain stimulation
14. Antidepressant agents and reversal of diurnal activity cycles in the rat
15. Antidepressant agents
16. Activity of antihistamines in laboratory antidepressant tests
17. Reward system depression following chronic amphetamine: antagonism by haloperidol
18. Stress, neurochemical substrates and depression: Concommitants are not necessarily causes
19. Salbutamol treatment of depression
20. Further characterization of the behavioural despair test in mice: Positive effects of convulsants
21. A reward reduction model of depression using self-stimulating rats: an appraisal
22. Contemporary theories of depression: critique and comparison
23. Behavioural effects of peer separation, isolation and reunion on adolescent male rhesus monkeys
24. Human personality development in an ethological light
25. Depression in bereavement and divorce
26. Desmethylimipramine, a new type of antidepressant drug
27. Serotonin-mimetic and antidepressant drugs on passive avoidance learning by olfactory bulbectomized rats
28. Effects of antidepressants and anticholinergics in a mouse “behavioural despair” test
29. The stress response: A new perspective
30. Effects of olfactory bulbectomy and domicile on stress induced corticosterone release in the rat
31. A new model for the detection of antidepressant drugs: Olfactory bulbectomy in the rat compared with existing models
32. Olfactory projection systems, drugs and behaviour: A review
33. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists
34. Potentiation of the behavioural effects of amphetamine
35. Neuroendocrine function in psychiatric disorders
36. Cerebrospinal fluid and plasma free cortisol levels in depression
37. Potentiation by tricyclic antidepressants of weight loss caused by amphetamine in rats
38. A critical study on RO-4-1284 antagonism in mice
39. Rat internal capsule lesion: a new test for detecting antidepressants
40. Interactions between reserpine, chlorpromazine and imipramine
41. Depression: Loss of reinforcers or loss of reinforcer effectiveness?
42. Behavioural and biochemical properties of the dopamine receptor
43. Awakening from reserpine sedation by alpha-methyl dopa
44. Differential effects of psychoactive drugs on aggressive responses in rats and mice
45. Learned helplessness in the perspective of the depressive disorders: Conceptual and definitional issues
46. The unipolar-bipolar distinction in the depressive disorders: implications for stress-onset interactions
47. Primary affective disorder —MMPI differences between unipolar and bipolar depressed subjects
48. On “learned helplessness”: The therapeutic effects of electroconvulsive shock
49. The effect, of imipramine and selected drugs on attack elicited by hypothalamic stimulation in the cat
50. Effects of tricyclic antidepressants on attack elicited by hypothalamic stimulation: Relation to brain biogenic amines
51. Reversal of reserpine-induced bradykinesia by alpha-methyldopa: New light on its modus operandi
52. The development of intersession habituation and emergence in socially reared and isolated rats
53. A possible role of opioid actions in endogenous depression
54. Anxiety and depression withdrawal: The primary effects of unpleasure
55. The DOPA response potentiation test and its use in screening for antidepressant drugs
56. Models of depression based on behavioural observations of experimental animals
57. Neurochemical and neuropharmacological investigations into the mechanisms of action of bupropion-HCl — a new atypical antidepressant agent
58. A functional analysis of depression
59. Increased intracranial self-stimulation in rats after long-term administration of desipramine
60. Specificity of brain stimulation reward in the rat
61. Learned helplessness, stress and the depressive disorders
62. Hyperactivity induced in rats by longterm isolation: further studies on a new animal model for the detection of antidepressants
63. Antidepressants selectively antagonize the hyperactivity induced in rats by long-term isolation
64. Neurotic depression: The concept of anxious depression
65. The sleep therapies of depression
66. A permanent change in brain function resulting from daily electrical stimulation
67. Mental effects of reserpine in man: A review
68. Evidence, that pathophysiology of depression and the mechanism of action of antidepressant drugs both involve alterations in circadian rhythms
69. The effect of antidepressants on behavioural despair in rats
70. Action of serotoninmimetics in the behavioural despair test in rats
71. The influence of LSD on locomotor activity in reserpinized mice
72. A comparison of imipramine, chlopromazine and related drugs in various tests involving autonomic functions and antagonism, of reserpine
73. Changes of brain monoamines in the animal model for depression
74. Electrical self-stimulation of the brain in man
75. The pleasure response: Studies by stereotaxic techniques in patients
76. Plasma cortisol as a predictor of individual depressive behaviour in rhesus monkeys (Macaca mulatta)
77. Animal testing and screening procedures in evaluating psychotropic drugs
78. Some factors influencing the effects of temporary mother-infant, separation. Some experiments with rhesus monkeys
79. Effects of various types of separation experience on rhesus monkeys 5 months later
80. Brain-stimulation reward and aversion in relation to behaviour
81. Hypothalamic control of feeding and self-stimulation
82. Selective block or rat mouse killing by antidepressants
83. The amygdala and depression
84. Effects of drugs on the mouse killing (muricide) test and its relationship to amygdaloid function
85. Empirical behavioural models of depression, with emphasis on tetrabenazine antagonism
86. Pharmacological modification of experimental depression in infant macaques
87. Life events and onset of primary affective disorders
88. Preclinical evaluation of AHR-118: A potential antidepressant drug
89. Current perspectives on childhood depression: An overview
90. Enkephalin and other peptides reduce passiveness
91. Animal models and human depressive disorders
92. Animal model of depression: Effects of electroconvulsive shock therapy
93. Animal model of depression: Pharmacological sensitivity of a hedonic deficit
94. A further parametric study of imipramine in an animal model of depression
95. Amitriptyline and scopolamine in an animal model of depression
96. Animal model of depression: tests of three structurally and pharmacologically novel antidepressant compounds
97. Further analysis of the specificity of a novel animal model of depression: Effects of an antihistaminic, antipsychotic and anxiolytic compound
98. Acute and chronic stress effects on open field activity in the rat: implications for a model of depression
99. Amphetamine and tranylcypromine in an animal model of depression: pharmacological specificity of the reversal effect
100. the reaction to separation in infant monkeys: Anaclitic, depression and conservation-withdrawal
101. Depression, can be induced in a bonnet macaque infant
102. Effects of antidepressants in the rat forced swimming test
103. Endogenomorphic depression: A conceptual and terminological revison
104. Consequences of commitment to and disengagement from incentives
105. Cyclic activity changes during extinction in rats: A potential model of depression
106. Effects of acute and subacute antidepressant treatment on kindled seizures in rats
107. Response sensitization and depression following long-term amphetamine treatment in a self-stimulation paradigm
108. Post-amphetamine depression of self-stimulation responding from, the substantia nigra: reversal by tricyclic antidepressants
109. Interactions of pharmacological agents which alter biogenic amine metabolism, and depression
110. REM latency: A psychobiological marker for primary depressive disease
111. Tricyclic and monoamine-oxidase inhibitor antidepressants: Clinical use
112. Effect, of psychoactive drugs on yohimbine-induced responses in conscious dogs. A study of antidepressant drugs
113. Effects of psychoactive drugs on yohimbine-induced responses in conscious dogs. A proposed screening procedure for anti-anxiety agents
114. Adrenergic nonspecific potentiation of yohimbine toxicity in mice by antidepressants and related drugs and antiyohimbine action of antiadrenergic and serotonergic drugs
115. Amphetamine and the reward system: evidence for tolerance and post-drug depression
116. Effects of chronic amphetamine or reserpine on self-stimulation: animal model of depression?
117. On the mode of action of mianserin
118. Effects of desmethylimipramine, (DMI) on learned helplessness
119. Effects of amphetamine on urinary and tissue catecholamines in rats after inhibition of its metabolism with desmethylimiparamine
120. A behavioural approach to depression
121. Endogenicity and reactivity as orthogonal dimensions in depression
122. Reinforcement and depression
123. Effects of electroconvulsive shock on the behaviour of normal and abnormal rhesus monkeys
124. Motherinfant separation in rhesus monkeys as a model of human depression: A reconsideration
125. Discriminating between reward and performance: A critical review of intracranial self-stimulation methodology
126. Selective factors, in memory
127. Life events and depressive disorder reviewed. I. Events as predisposing factors
128. Life events and depressive disorders reviewed. II. Events as precipitating factors
129. The action of monoaminergic, cholinergic and gabaergic compounds in the olfactory bulbectomized rat model of depression
130. Learned helplessness: Theory and evidence
131. Influence of control of shock on subsequent shock-elicited aggression
132. Yohimbine potentiation as a predictor of antidepressant action
133. The new antidepressant pirlindone: A comparison with imipramine and tranylcypromine
134. Demonstration of anti-depressant or stimulant properties of imipramine in experimental animals
135. Animal model of depression: Review of evidence and implications for research
136. Chlorpromazine treatment of disturbed monkeys
137. Historical background in children with affective disorders
138. Effects of environmental restriction upon the chimpanzee's responsiveness to objects
139. Learned helplessness and depression
140. The effects of isolation rearing on behavioural inhibition in the rat
141. Effect of imipramine-like compounds and chlorpromazine on reserpine-hypothermia in mice and amphetamine-hyperthermia in rats
142. Pre- and postsynaptic serotonergic manipulations in an animal of depression
143. Postsynpatic action by four antidepressive drugs in an animal model of depression
144. Blood and brain concentrations of imipramine, clomipramine and their monomethylated metabolites, after oral and intramuscular administration in rats
145. The symptoms of major depression
146. Swimming mice: In search, of an animal model for human depression
147. Delayed emergence of antidepressant efficacy following withdrawal in olfactory bulbectomized rats
148. Effects of hunger and male sex hormone on selfstimulation of the brain
149. Escapability and generalization: Effect on behavioural despair
150. Classification of depressed patients: A cluster analysis derived grouping
151. Recent life events in the development of the depressive disorders
152. Drug treatment of depression in children
153. Psychosomatic aspects of catecholamine depletion: Comparative aspects of metabolic, endocrine and affective changes
154. Reversal of learned helplessness by imipramine
155. Behavioural despair
156. Behavioural, despair in mice: A primary screening test for antidepressants
157. Depression: A new animal model sensitive to antidepressant treatment
158. Behavioural despair in rats, a new model sensitive to antidepressant treatments
159. Behavioural despair in rats and mice: Strain differences and the effects of imipramine
160. Immobility induced by forced swimming in rats: Effects of agents which modify central catecholamine and serotonin activity
161. The clinical phenomenology of childhood depression
162. The increase in the toxicity of yohimbine induced by imipramine and other drugs in mice
163. Attachment, loss and depression
164. Responses, of young children to separation from their mothers
165. Inescapable shock interferes with the acquisition of a free appetitive operant
166. Inescabable shock interferes with the acquisition of a low-activity response in an appetitive context
167. Further studies on a novel animal model of depression: therapeutic effects of a tricyclic antidepressant
168. Disrupted, 24-hour patterns of cortisol secretion in psychotic depression
169. The effects of psychomotor stimulants on stereotypy and locomotor activity in socially deprived and control rats
170. The effects of isolation rearing on exploration in the rat
171. The evaluation of central nervous system stimulants in a new laboratory test for antidepressants
172. The evaluation of a new animal method for the prediction of clinical antidepressant activity
173. Exploration of the antidepressant potential of iprindole
174. Non-specificity of “behavioural despair” as an animal model of depression
175. Behavioural effects of interacting imipramine and other drugs with d-amphetamine, cocaine and tetrabenazine
176. Selective supression of rapid eye movement sleep (REMS) in cats by typical and atypical antidepressants
177. An analysis of amphetamine toxicity and patterns of use
178. Adaptive role role of depression in health and disease
179. Theoretical implications of drug-induced adaptive regulation for a biogenic amine hypothesis of affective disorder
180. Learned helplessness in the rat
181. Learned helplessness in the rat: Reversibility, time course and immunization
182. Electrical stimulation and self-stimulation in man with chronic implanted electrodes. Interpretation and pitfalls of results
183. Specificity of the learned helplessness model of depression
184. An overview of new “second generation” antidepressant compounds: Research and treatment implications
185. The effect of imipramine on central adrenergic mechanisms
186. Antagonism to reserpine induced depression by imipramine, releated psychoactive drugs and some autonomic agents
187. Trazodone—A new type of antidepressant: A discussion of pharmacological data and their clinical implications
188. Behavioural withdrawal following several psychoactive drugs
189. Tricyclic antidepressants and serotonin manipulations in an animal model of depression utilizing chronic intermittent stress
190. Effects of centrally active drugs on experimentally-induced aggression in rodents
191. Structural relationship and potency of agents which selectively block mouse killing (muricide) behaviour in rats
192. Anaclitic depression
193. New methods for evaluating stimulants and antidepressants
194. Possible mode of antidepressive action of imipramine
195. Observations concerning adrenergic functions and antidepressant activity
196. The action of desmethylimipramine in counteracting sedation and cholinergic effects of reserpine-like drugs
197. On the mechanism of amphetamine potentiation by desipramine
198. Mode of action of antidepressant drugs
199. Factors affecting responses to social separation in rhesus monkeys
200. Effect of repetitive infantinfant separation of young monkeys
201. Effect of maternal and peer separations on young monkeys
202. Effects of impramine treatment on separation-induced social disorders in rhesus monkeys
203. Rat internal capsule lesion: further characterization of antidepressant screening potential
204. The role of life events in depressive illness: is there a substantial causal connection?
205. Comparative pharmacological studies with Tofranil, Pertofran and Ensidon
206. The effect of early deprivation on the social behaviour of adolescent chimpanzees
207. Clinical use of monoamine oxidase inhibitors
208. Mouse-killing behaviour (muricide) in the rat and the effect of antidepressants
209. Psychoactive drug effects on behavioural changes induced by prolonged socio-environmental deprivation in rats
210. Influence of imipraminelike drugs on the metabolism of amphetamine
211. Different central effects of the 5-HT antagonists mianserin and cyproheptadine
212. Development of psychotropic drugs
213. Olfactory bulb ablation in the rat: Behavioural changes and their reversal by antidepressant drugs
214. Chronic administration of electroconvulsive shock: Effects on mouse killing activity and brain monoamines in rats
215. The applicability of inescapable shock as a source of animal depression
216. The effects of antihistamines in a modified behavioural despair test
217. Effects of psychotropic drugs injected into the limbic structures on mouse-killing behaviour in the rat with olfactory bulb ablation
218. Amphetamine withdrawal: Affective state, sleep patterns and MHPG excretion
219. The influence of psychoactive drugs on brain self-stimulation in rats: A review
220. Circadian rhythm mechanisms in affective illness and in antidepressant drug action
221. Models of cognitive impairment: Cognitive changes in depression
222. Biochemical and pharmacological studies on an animal model of hyperactivity states
223. Changes in brain catecholamine turnover and receptor sensitivity induced by social deprivation in rats
224. Effects of coping responses on stress
225. Behavioural depression produced by an uncontrollable stressor: relationship to noreprinephrine, dopamine, and serotonin levels in various regions of rat brain
226. A reappraisal of the interaction between tricyclic antidepressants and reserpine-like drugs
227. Alteration of intracranial self-stimulation in mice following inescapable stress